232 related articles for article (PubMed ID: 2974065)
1. Immunologically mediated regression of a murine lymphoma after treatment with anti-L3T4 antibody. A consequence of removing L3T4+ suppressor T cells from a host generating predominantly Lyt-2+ T cell-mediated immunity.
Awwad M; North RJ
J Exp Med; 1988 Dec; 168(6):2193-206. PubMed ID: 2974065
[TBL] [Abstract][Full Text] [Related]
2. Specificity of the T cells that mediate and suppress adoptive immunotherapy of established tumors.
Dye ES; North RJ
J Leukoc Biol; 1984 Jul; 36(1):27-37. PubMed ID: 6234371
[TBL] [Abstract][Full Text] [Related]
3. Cellular basis of immunologic interactions in adoptive T cell therapy of established metastases from a syngeneic murine sarcoma.
Ward BA; Shu S; Chou T; Perry-Lalley D; Chang AE
J Immunol; 1988 Aug; 141(3):1047-53. PubMed ID: 3260908
[TBL] [Abstract][Full Text] [Related]
4. Effects of purified anti-Lyt-2 mAb treatment on murine listeriosis: comparative roles of Lyt-2+ and L3T4+ cells in resistance to primary and secondary infection, delayed-type hypersensitivity and adoptive transfer of resistance.
Czuprynski CJ; Brown JF
Immunology; 1990 Sep; 71(1):107-12. PubMed ID: 2120126
[TBL] [Abstract][Full Text] [Related]
5. CD4-CD8- T cell receptor alpha beta T cells: generation of an in vitro major histocompatibility complex class I specific cytotoxic T lymphocyte response and allogeneic tumor rejection.
Mieno M; Suto R; Obata Y; Udono H; Takahashi T; Shiku H; Nakayama E
J Exp Med; 1991 Jul; 174(1):193-201. PubMed ID: 1905338
[TBL] [Abstract][Full Text] [Related]
6. Mediation of in vivo tumor-neutralizing activity by Lyt-2+ as well as L3T4+ T cell subsets.
Yoshioka T; Sato S; Ogata M; Sakamoto K; Sano H; Shima J; Yamamoto H; Fujiwara H; Hamaoka T
Jpn J Cancer Res; 1988 Jan; 79(1):91-8. PubMed ID: 2965692
[TBL] [Abstract][Full Text] [Related]
7. Regulation of Ia+ reticulum cell sarcoma (RCS) growth in syngeneic SJL/J mice. I. Inhibition of tumor growth by passive administration of L3T4 monoclonal antibody before or after tumor inoculation.
Ohnishi K; Bonavida B
J Immunol; 1987 Jun; 138(12):4524-9. PubMed ID: 2953807
[TBL] [Abstract][Full Text] [Related]
8. T-cell subsets, IFN-gamma production and efferent specificity in anti-parental tumor immunity induced by mouse sensitization with xenogenized variant cells.
Bianchi R; Fioretti MC; Romani L; Grohmann U; Cenci E; Puccetti P
Int J Cancer; 1990 Oct; 46(4):653-7. PubMed ID: 2120136
[TBL] [Abstract][Full Text] [Related]
9. In vitro differentiation of T-cells capable of mediating the regression of established syngeneic tumors in mice.
Shu S; Chou T; Rosenberg SA
Cancer Res; 1987 Mar; 47(5):1354-60. PubMed ID: 3102046
[TBL] [Abstract][Full Text] [Related]
10. Cellular interactions and the role of interleukin 2 in the expression and induction of immunity against a syngeneic murine sarcoma.
Chou T; Shu S
J Immunol; 1987 Sep; 139(6):2103-9. PubMed ID: 2957448
[TBL] [Abstract][Full Text] [Related]
11. Requirements for the generation of a Lyt-2+ T-cell proliferative response to a syngeneic tumor in the absence of L3T4+ T-cells.
Kern DE; Klarnet JP; Cheever MA; Greenberg PD
Cancer Res; 1990 Oct; 50(19):6256-63. PubMed ID: 2144789
[TBL] [Abstract][Full Text] [Related]
12. Cyclophosphamide-induced immunologically mediated regression of a cyclophosphamide-resistant murine tumor: a consequence of eliminating precursor L3T4+ suppressor T-cells.
Awwad M; North RJ
Cancer Res; 1989 Apr; 49(7):1649-54. PubMed ID: 2522344
[TBL] [Abstract][Full Text] [Related]
13. Selective suppression of the generation of anti-tumor L3T4+ but not of Lyt-2+ T cell-mediated immunity in the tumor-bearing state.
Sano H; Sato S; Shima J; Tada T; Fujiwara H; Hamaoka T
Jpn J Cancer Res; 1988 Jul; 79(7):857-65. PubMed ID: 3139599
[TBL] [Abstract][Full Text] [Related]
14. T-cell immunity to murine Moloney sarcoma virus-induced tumours: L3T4+ T cells are necessary for resistance to primary sarcoma growth, but Lyt-2+ T cells are required for resistance to secondary tumour cell challenge.
Bateman WJ; Jenkinson EJ; Owen JJ
Immunology; 1987 Jul; 61(3):317-20. PubMed ID: 2956180
[TBL] [Abstract][Full Text] [Related]
15. Interleukin 1-induced, T cell-mediated regression of immunogenic murine tumors. Requirement for an adequate level of already acquired host concomitant immunity.
North RJ; Neubauer RH; Huang JJ; Newton RC; Loveless SE
J Exp Med; 1988 Dec; 168(6):2031-43. PubMed ID: 3143799
[TBL] [Abstract][Full Text] [Related]
16. Antibodies to the L3T4 and Lyt-2 molecules interfere with antigen receptor-driven activation of cloned murine T cells.
Moldwin RL; Havran WL; Nau GJ; Lancki DW; Kim DK; Fitch FW
J Immunol; 1987 Aug; 139(3):657-64. PubMed ID: 2955046
[TBL] [Abstract][Full Text] [Related]
17. Effects of anti-Lyt-2 and anti-L3T4 monoclonal antibodies on the function of cytotoxic T lymphocyte/helper T lymphocyte hybrid T cell clones.
Havran WL; Fitch FW
J Immunol; 1988 Sep; 141(6):1808-12. PubMed ID: 2459190
[TBL] [Abstract][Full Text] [Related]
18. Phenotype analyses and cellular mechanisms of the pre-effector T-lymphocyte response to a progressive syngeneic murine sarcoma.
Sakai K; Chang AE; Shu SY
Cancer Res; 1990 Jul; 50(14):4371-6. PubMed ID: 2114215
[TBL] [Abstract][Full Text] [Related]
19. Contrasuppressor cells that break oral tolerance are antigen-specific T cells distinct from T helper (L3T4+), T suppressor (Lyt-2+), and B cells.
Kitamura K; Kiyono H; Fujihashi K; Eldridge JH; Green DR; McGhee JR
J Immunol; 1987 Nov; 139(10):3251-9. PubMed ID: 3500210
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a CD4(L3T4)-positive cytotoxic T cell clone that is restricted by class I major histocompatibility complex antigen on FBL-3 tumor cell.
Matsubayashi Y; Zenita K; Morioka A; Iwashiro M; Masuda T; Uchino H; Fujita T; Kuribayashi K
Immunobiology; 1989 Nov; 180(1):33-46. PubMed ID: 2483152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
